News

Enlarge image

Clinical trialsSwitzerlandNetherlands

Roche reports new T-DM1 results

30.09.2013 - New results with Roche’s antibody drug conjugate T-DM1 suggest the drug is a more effective breast cancer therapy than trastuzumab and lapatinib.

Interim results from the TH3RESA Phase III study were presented at the European Cancer Congress in Amsterdam. In HER2-positive breast cancer patients whose cancer was inoperable,had recurred or metastasised after several treatments including trastuzumab and lapatinib, progression-free survival (PFS) increased by nearly three months.

In 602 patients randomised to receive 3.6 mg/kg intravenous infusion of the antibody-drug conjugate (ADC) every three weeks compared to a treatment of their physician's choice, a PFS of 3.3 months was observed for the TPC patients compared to 6.2 months for patients receiving T-DM1. Among the T-DM1 patients, 31.3% showed a response to the drug, compared to 8.6% of the TPC patients. An interim analysis of overall patient survival showed a similar trend, but it did not reach the level at which a statistically significant benefit for T-DM1 treatment could be confirmed. Generally, there were fewer serious adverse side-effects in the T-DM1 patients than in the TPC group.

Lead investigator Hans Wildiers said: "This study shows that even in heavily pre-treated women, 75% of whom had cancer that has spread to the internal organs, T-DM1 nearly doubles progression-free survival. Few drugs have been able to achieve both improved progression-free survival and a better toxicity profile."

T-DM1 links Roche’s Her2-specific antibody trastuzumab with the tubulin blocker emtansine (DM1) to target and kill breast cancer cells that overexpress the HER2 protein on their cell surfaces. The ADC has already been approved as a treatment for metastatic and recurrent breast cancer–patient in which herceptin + taxane therapy failed under the brand name Kadcyla.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-04/roche-reports-new-t-dm1-results.html

Clinical TrialsFrance

26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.

M&AUKSweden

24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

ApprovalEU

04.08.2016 After a two-year pilot period, the EMA has published its report on its adaptive pathways approach. The agency plans to “explore the concept further” and will continue to accept proposals.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NORDIC NANOVECTOR (N)34.00 NOK6.58%
  • RENEURON (UK)2.88 GBP4.73%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)11.56 USD-7.52%
  • VITA 34 (D)4.14 EUR-7.17%
  • ADOCIA (F)53.20 EUR-5.67%

TOP

  • NORDIC NANOVECTOR (N)34.00 NOK38.8%
  • KARO BIO (S)42.00 SEK27.3%
  • MOLMED (I)0.42 EUR27.3%

FLOP

  • BIONOR PHARMA (N)0.44 NOK-22.8%
  • E-THERAPEUTICS (UK)11.50 GBP-14.1%
  • ZEALAND PHARMA (DK)112.00 DKK-13.5%

TOP

  • NICOX (F)10.07 EUR430.0%
  • SAREUM HOLDINGS (UK)0.76 GBP245.5%
  • GENMAB (DK)1094.00 DKK85.0%

FLOP

  • BB BIOTECH (D)44.29 EUR-83.1%
  • EVOCUTIS (UK)0.04 GBP-77.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)5.65 SEK-75.4%

No liability assumed, Date: 28.08.2016